MyxoTech jobs and careers

About MyxoTech

As the pharmaceutical industry continues to advance, there is an increasing number of identified drug targets and new modalities that require novel small molecule space. MyxoTech offers a library of novel chemistry produced by a group of bacteria that exist on the fringe of microbial dark matter. This pool of small molecules contains proven bioactives that act on diverse targets. Corallopyronin A, projected for phase I clinical trials in 2026 for treatment of filarial infection, and breast cancer drug Ixabepilone's precursor epothilone B exemplify the value of the library. We additionally provide a menu of downstream services, including drug lead and production titer optimization. MyxoTech is an outsourced preclinical natural product pipeline adaptable for you drug development needs.